论文部分内容阅读
目的:探讨山东地区原发性高血压患者血管紧张素Ⅱ2型受体基因A1675G多态性与钙拮抗剂降压效果的相关性。方法:对300例原发性高血压患者,用硝苯地平控释片进行为期8周的降压治疗,用PCR结合高分辨率溶解曲线、基因测序方法检测患者血管紧张素Ⅱ2型受体基因多态性。结果:257例患者完成试验,其中女127例,男130例。在女性患者中基因型AA、AG和GG收缩压和舒张压降压幅度及药物疗效方面差异均无统计学意义(P>0.05),男性患者中基因型AA和GG在降压幅度及药物疗效方面差异亦无统计学意义(P>0.05)。结论:在山东地区高血压患者中,A1675G多态性可能不会影响硝苯地平控释片降压效果。
Objective: To investigate the relationship between angiotensin Ⅱ type 2 receptor gene A1675G polymorphism and antihypertensive effects of calcium antagonists in patients with essential hypertension in Shandong Province. Methods: 300 hypertensive patients with nifedipine controlled release tablets for 8 weeks of antihypertensive treatment by PCR combined with high resolution lysis curve, gene sequencing method to detect angiotensin Ⅱ type 2 receptor gene Polymorphism. Results: A total of 257 patients completed the trial, of whom 127 were female and 130 were male. The genotypes of AA, AG and GG had no significant differences in systolic and diastolic blood pressure (BP) and drug efficacy between female patients (P> 0.05). The genotypes AA and GG in male patients were significantly different The difference was not statistically significant (P> 0.05). Conclusion: In the hypertensive patients in Shandong Province, A1675G polymorphism may not affect the nifedipine controlled release tablets antihypertensive effect.